CNS PHARMACEUTICALS, INC.
2100 WEST LOOP SOUTH
SUITE 900
HOUSTON TX 77027
October 2, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Re: | CNS Pharmaceuticals, Inc. | |
Registration Statement on Form S-1 | ||
Registration No. 333-249068 |
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 P.M. (Eastern Time) on October 6, 2020, or as soon thereafter as possible on such date.
Very truly yours, | |
CNS Pharmaceuticals, Inc. | |
By: /s/ Christopher Downs | |
Name: Christopher Downs | |
Title: Chief Financial Officer |